Navigation Links
Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting

dy and baseline of minus 2.2 ± 3.8 in the safinamide-treated group versus minus 1.2 ± 3.5 in the placebo group; p=0.0248; 95% CI=[-1.8;-0.1]).

Safinamide was also studied for effects on cognition. Compared with patients on dopamine agonist monotherapy, the addition of safinamide was associated with an improvement in cognitive function as shown by an improvement in tests assessing spatial working memory, strategic target detection and auditory number sequencing.

The side effects observed in the safinamide group were similar to those observed in the placebo group.

The trial was conducted in Europe, South America and Asia. A total of 270 early stage Parkinson’s disease patients (less than 5 years of disease) treated with a stable dose of a single dopamine agonist for at least 4 weeks were randomized to one of the three arms of the study to receive either safinamide at a dose of 50 to 100 mg once daily (90 patients), or safinamide at a dose of 150 to 200 mg once daily (90 patients) or matching placebo tablets (90 patients), as an add-on treatment to dopamine agonist therapy.

The higher safinamide dose-range of 150 to 200 mg per day did not offer any incremental advantage over safinamide 50 to 100 mg per day dose-range based on UPDRS scoring.

A one-year (52-week) extension phase of this study is ongoing. A second Phase III pivotal study of safinamide, in patients with mid-to-late stage Parkinson’s disease with motor fluctuations treated with a stable dose of levodopa, was initiated in November 2006.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and restless leg syndrome, as per the agreement signed with Newron in October 2006.

1 The UPDRS is one of the mos
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:4/17/2015)... , April 17, 2015 Nonin Medical, ... that President and Chief Operating Officer Steve Bucholz ... Isaacson is expanding his role as Chief Executive ... role as Chief Technology Officer. Operations will transition to ... " Steve Bucholz has been instrumental to Nonin ...
(Date:4/17/2015)... WOONSOCKET, R.I , April 17, 2015 ... holding a conference call on Friday, May 1, 2015, ... discuss its first quarter financial results. An ... simultaneously through the Investor Relations portion of the CVS ... webcast, visit http://investors.cvshealth.com . This webcast will be ...
(Date:4/17/2015)... ASSESS shows   plasma circulating ... viable alternative to tumour biopsy   IGNITE ... advanced NSCLC   AstraZeneca today presented results from ... DNA (ctDNA) testing for epidermal growth factor receptor (EGFR) mutation ... cancer (NSCLC) in clinical practice. [ 1 ] ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... Makes Rapid Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic ... Medical today announced that one of the leading ... performed the first case in the world utilizing ... orthopedic surgery. The IlluminOss Photodynamic Bone Stabilization ...
... Feb. 24 BioTrends is pleased to announce the fielding of ... (R) . Takeda Pharmaceutical Company Limited announced that they ... febuxostat) on February 13, 2009. Uloric (R) ... and represents the first product for gout that has been approved ...
Cached Medicine Technology:IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 2IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile 3
(Date:4/18/2015)... (PRWEB) April 18, 2015 "I recognized ... stretchers in healthcare facilities," said an inventor from Cincinnati, ... storage system." , He developed the Slyde Door to ... used in healthcare facilities. It provides convenient storage space ... are more stretchers available for patients. , This ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... April 18, 2015 Patients who undergo ... developing mesothelioma later in life, but the disease is ... that is unrelated to radiation. Surviving Mesothelioma has just ... website. Click here to read it now. ... the cases of 45 patients who had both a ...
(Date:4/18/2015)... than 2000 styles of newly designed prom dresses are ... carrying celebrity inspired special occasion dresses. With the prom ... for their prom. For those who are still looking ... be an ideal choice. , "We have by ... the most loved styles seen at this years major ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part ... latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... In a turbulent world, people may find themselves in dangerous ... their first move, but some situations can be avoided if ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2
... days after trauma, developers say , WEDNESDAY, Sept. 12 ... monitor blood flow through the brain in real time, ... head injuries. , Brain trauma is a top killer ... suffer brain injuries annually, according to the U.S. Centers ...
... Scientists have identified a distinct subpopulation of cancer stem ... deadly human pancreatic cancer. The research, published by Cell ... Stem Cell, provides insight into the role of CSCs ... directions for development of more effective therapeutics. , Pancreatic ...
... - Treatment in private doctors, offices with FDA-approved medication could, ... ... killers-, RICHMOND, Va., Sept. 12 ... released by the Substance Abuse and,Mental Health Services Administration (SAMHSA), shows that ...
... EXTON, Pa., Sept. 12 Kensey Nash Corporation,(Nasdaq: ... earnings results,for its first quarter ended September 30, 2007 ... Joe Kaufmann, President and CEO, will be hosting ... 2007 at 9:00 A.M.,Eastern Time. To participate in ...
... against macular degeneration, study finds , WEDNESDAY, Sept. 12 ... the yellow plant pigments lutein and zeaxanthin may have ... a leading cause of irreversible blindness among the elderly. ... supported by the U.S. government, looked at more than ...
... 12, 2007 Rice University chemists have discovered a way ... onto tiny gold spheres. The result is a tiny ball, ... with the drug. , Paclitaxel, which is sold under the ... their inner works. , "Paclitaxel is one of the most ...
Cached Medicine News:Health News:Imaging Software Helps Track, Treat Injured Brains 2Health News:Cancer stem cell subpopulation drives metastasis of human pancreatic cancer 2Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 2Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 3Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 4Health News:Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults 5Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Taxol bristle ball: a wrench in the works for cancer 2
... double spot test is a rapid, ... antibodies to T. cruzi in human ... samples. This test is intended primarily ... reactive samples should be confirmed by ...
... is intended for the immunochromatographic, qualitative ... samples.,Smart Strip Gonorrhea is based on ... the determination of gonorrhea antigen in ... urinary system as an aid in ...
Inquire...
For the rapid determination of human chorionic gonadotropin (hCG) in urine and serum. The test strip is used to obtain a visual qualitative result....
Medicine Products: